Arvinas, a clinical-stage biotech company, announced it will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026. The company is known for developing VEPPANU, the first FDA-approved PROTAC drug for certain advanced breast cancers, in partnership with Pfizer. Arvinas is advancing multiple investigational drugs targeting diseases like neurodegenerative disorders, mutated cancers, and lymphoma. This presentation will showcase their innovative protein degradation platform and ongoing clinical programs, signaling potential growth and new treatment options.
The AI cryptocurrency sector reached a market cap of about $26.6 billion in May 2026, led by projects like Chainlink and NEAR Protocol. Ruvi AI (RUVI) stands out by integrating over 20 AI models into a decentralized platform that rewards contributors...
ImPact Biotech presented updated positive data from its Phase 1 trial for Padeliporfin VTP in locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) and Phase 3 ENLIGHTED trial in low-grade upper tract urothelial carcinoma (LG-UTUC) at ASCO 2026...
Ripple has evolved into a full-service crypto infrastructure provider for enterprises, now offering payments, custody, tokenization, liquidity, and treasury management. This expansion reflects Ripple's shift beyond cross-border payments to serve broa...
Cardano's ADA price is testing a critical support zone around $0.243 to $0.247, a level significant since 2021, with potential for a rebound if buyers hold this floor. Meanwhile, Cardano's stablecoin market cap surged 60% in the past week, led by USD...
Ripple (XRP) and Stellar (XLM) are positioned as complementary blockchain networks that could jointly define the future of global payments, much like Visa and Mastercard in traditional finance. Both focus on fast, low-cost cross-border transfers and ...
